Induction chemotherapy followed by up-front autologous stem cell transplantation may have a survival benefit in high-risk diffuse large B-cell lymphoma patients

Experimental Hematology

Volumn 44, Issue 1, 2016, Pages 3-13

  Shin, Ho Jin ^a   Yoon, Dok Hyun ^b   Lee, Ho Sup ^c   Oh, Sung Yong ^d   Yang, Deok Hwan ^e   Kang, Hye Jin ^f   Chong, So Young ^g   Park, Yong ^h   Do, YoungRok ⁱ   Lim, Sung Nam ^j   Jo, Jae Cheol ^k   Lee, Won Sik ^l   Chung, Joo Seop ^a  

^a Pusan National University School of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Kosin University College of Medicine   (South Korea)

^d Dong A University College of Medicine   (South Korea)

^e Chonnam National University Research Institute of Medical Sciences   (South Korea)

^f Korea Cancer Center Hospital   (South Korea)

^g Bundang CHA Hospital   (South Korea)

^h Korea University College of Medicine   (South Korea)

ⁱ Dongsan Medical Center   (South Korea)

^j Department of Internal Medicine   (South Korea)

^k University of Ulsan College of Medicine   (South Korea)

^l Inje University College of Medicine   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; MONOCLONAL ANTIBODY; R-CHOP PROTOCOL; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; INDUCTION CHEMOTHERAPY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; CLINICAL TRIAL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; MULTICENTER STUDY; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; VINCRISTINE; YOUNG ADULT;

EID: 84949730904     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2015.08.008     Document Type: Article

References (19)

1. Ziepert M., Hasenclever D., Kuhnt E., et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010, 28:2373-2380.
2. Sehn L.H., Berry B., Chhanabhai M., et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007, 109:1857-1861.
3. Gisselbrecht C., Glass B., Mounier N., et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2012, 28:4184-4190.
4. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995, 333:1540-1545.
5. Vellenga E., van Putten W.L., van 't Veer M.B., et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: A prospective randomized HOVON trial. Blood 2008, 111:537-543.
6. Kluin-Nelemans H.C., Zagonel V., Anastasopoulou A., et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: Randomized phase III EORTC study. J Natl Cancer Inst 2001, 93:22-30.
7. Gisselbrecht C., Lepage E., Molina T., et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002, 20:2472-2479.
8. Olivieri A., Santini G., Patti C., et al. Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: Long-term results by the NHLCSG. Ann Oncol 2005, 16:1941-1948.
9. Greb A., Bohlius J., Trelle S., et al. High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma: Results of a comprehensive meta-analysis. Cancer Treat Rev 2007, 33:338-346.
10. Strehl J., Mey U., Glasmacher A., et al. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: A meta-analysis. Haematologica 2003, 88:1304-1315.
11. Schmitz N., Nickelsen M., Ziepert M., et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: An open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol 2012, 13:1250-1259.
12. Stiff P.J., Unger J.M., Cook J.R., et al. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med 2013, 369:1681-1690.
13. Cheson B.D., Pfistner B., Juweid M.E., et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
14. Adde M., Enblad G., Hagberg H., Sundstrom C., Laurell A. Outcome for young high-risk aggressive B-cell lymphoma patients treated with CHOEP-14 and rituximab (R-CHOEP-14). Med Oncol 2006, 23:283-293.
15. Gang A.O., Strom C., Pedersen M., et al. R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14: A population-based investigation from the Danish Lymphoma Group. Ann Oncol 2012, 23:147-153.
16. Papajik T., Raida L., Faber E., et al. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission. Neoplasma 2008, 55:215-221.
17. Mounier N., Gisselbrecht C., Briere J., et al. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: A cohort study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2004, 22:2826-2834.
18. Haioun C., Lepage E., Gisselbrecht C., et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol-A groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 2000, 18:3025-3030.
19. Milpied N., Deconinck E., Gaillard F., et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004, 350:1287-1295.